TRENDS IN LIST PRICES, NET PRICES, AND DISCOUNTS FOR SELF-ADMINISTERED DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS

Author(s)

Barber N1, San-Juan-Rodriguez A2, Hernandez I2, Good CB3, Gellad WF4
1University of Pittsburgh, Sugarloaf, PA, USA, 2University of Pittsburgh, Pittsburgh, PA, USA, 3Veterans Health Administration Center for Medication Safety (VA MedSAFE), University of Pittsburgh Medical Center, Pittsburgh, PA, USA, 4Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA

OBJECTIVES: To describe trends in list prices, net prices, and discounts for self-administered disease-modifying therapies (DMTs) for multiple sclerosis (MS) from 2007-2019.

METHODS: We obtained 2007-2019 pricing data for dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1A, interferon beta-1B, peginterferon beta-1A, and teriflunomide from SSR Health, which provides quarterly estimates of list prices, net prices, and discounts in Medicaid and other payers for branded products manufactured by publicly traded companies. For each drug and year, we calculated average list and net annual costs of treatment based on FDA-approved dosing; and average discounts in Medicaid and other payers.

RESULTS: From 2007-2019, list prices of self-administered MS DMTs increased by 4.5-fold or 13.4% each year, from an annual cost of treatment of $20,862 to $93,496. Net prices increased by 3.8-fold or 12.2% each year, from an annual cost of treatment of $17,880 to $68,058. Annual increases in list and net prices were higher in 2007-2014, when they averaged 17-18%, but slowed down after 2015, with annual increases of 10.9% and 6.9% in 2015-2017. After 2017, list prices increased by an annual average of 5.9%, while net prices leveled off. From 2007-2019, manufacturer discounts for self-administered MS DMTs increased, on average, by 40.4 percentage points for Medicaid, from 26.7% to 67.1%; and by 7.2% for payers other than Medicaid, from 8.5% to 15.7%.

CONCLUSIONS: Prices of self-administered MS DMTs rose dramatically in 2007-2019, even after accounting for manufacturer discounts. Recent leveling off of net prices was particularly driven by increases in manufacturers discounts for payers other than Medicaid.

Conference/Value in Health Info

2020-05, ISPOR 2020, Orlando, FL, USA

Code

PBI11

Topic

Economic Evaluation

Disease

Biologics and Biosimilars, Neurological Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×